Germantown, MD, USA (February 07, 2024) – Amarex Clinical Research, LLC, an NSF company, announces December 2023 marked its 25th year advancing patient access to safe and effective clinical products through delivery of outstanding regulatory and clinical trial services to Sponsors within the life sciences industry.
Amarex was founded in 1998 by scientists from diverse backgrounds in academia, industry, and the FDA. Born from a vision of wanting better services from CRO vendors by correcting the many inefficiencies and deficiencies in the management and conduct of clinical trials, our founders revisited the clinical trial process and developed improved, cost-effective methods for clinical product development without sacrificing quality. Amarex’s unmatched value to Sponsors continues to differentiate Amarex from the competition by assigning senior level staff to every project, optimizing time and cost with efficient and effective processes and procedures, building true collaborative partnerships with Sponsors, and through a commitment to long-term client relationships in order to achieve successful clinical development program outcomes.
“We’re proud to celebrate 25 years of successfully expediting patient access to safe and effective clinical products,” said David Lonza, President, Amarex. “We look forward to bringing more of our clients’ products to market over the next 25 years as we continue to provide customized support to each clinical study we conduct.”
Peter Frantz, Senior Vice President, Business Operations at Amarex commented, “This milestone reflects Amarex’s success at providing quality and cost-efficient clinical trial services on over 700 projects with more than 250 different clients. We are proud to have had a role in helping to bring 26 new products to market to improve patients’ lives. As we celebrate this major achievement, we extend our sincere appreciation to our staff, clients, trial participants, research sites, vendors, stakeholders, regulators, and our global community at large. Thank you for your instrumental role in Amarex’s journey.”
About Amarex Clinical Research, LLC, an NSF company
Amarex Clinical Research, LLC, an NSF company, is a global, full-service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research. Their combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides services in Project Management: Phase I-IV, BE/BA, PK/PD; Regulatory Affairs: FDA Applications and meetings, applications to International Health Authorities, GxP Compliance Audits; Clinical Operations; Adaptive Study Designs; Statistical Analysis; Data Management; Medical Monitoring; Safety and Pharmacovigilance; and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products assisted by quality, cost-efficient services. For more information visit www.amarexcro.com.
Amarex Contact:
Patrick J. Burke
Business Development
This email address is being protected from spambots. You need JavaScript enabled to view it.